Administration of ammonium chloride aggravates, while short-term administration of sodium or potassium bicarbonate lessens the development of polycystic kidney disease in Han:SPRD rats. We have conducted studies to determine whether the protection afforded by the administration of sodium bicarbonate is sustained and prevents development of uremia during chronic administration and whether the effects of the administration of ammonium chloride and sodium bicarbonate are also observed in a different model of polycystic kidney disease, the CD1-pcy/pcy mouse. We found that chronic administration of 200 mM sodium bicarbonate to Han:SPRD rats inhibited cystic enlargement and prevented the subsequent development of interstitial inflammation, chronic fibrosis, and uremia. We also found that, while the administration of ammonium chloride has similar effects in Han:SPRD rats and CD1-pcy/pcy mice, the administration of sodium bicarbonate is only protective in the Han:SPRD rats. This probably reflects differences in these models (predominately involvement of proximal tubules in Han:SPRD rats and of collecting ducts and distal tubules in pcy/pcy mice) and the different location and nature of the renal metabolic responses to the administration of acid or alkaline load.

Keywords:
Polycystic kidney disease, Han:SPRD rats, pcy/pcy mice, Sodium bicarbonate, Ammonium chloride
1.
Torres VE, Mujwid DK, Wilson DM, Holley KH: Renal cystic disease and ammoniagenesis in Han:SPRD rats. J Am Soc Nephrol 1994;5:1193–1200.
2.
Cowley BD Jr, Grantham JJ, Muessel MJ, Kraybill AL, Gattone VH II: Modification of disease progression in rats with inherited polycystic kidney disease. Am J Kidney Dis 1996;27:865–879.
3.
Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH II: Autosomal dominant polycystic kidney disease in the rat. Kidney Int 1993;43:522–534.
4.
Gattone VH, Cowley BD Jr, Barash BD, Nagao S, Takahashi H, Yamaguchi T, Grantham JJ: Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents. Am J Kidney Dis 1995;25:302–313.
5.
Gattone VH II, Calvet JP, Cowley BD Jr, Evan AP, Shaver TS, Helmstadter K, Grantham JJ: Autosomal recessive polycystic kidney disease in a murine model, a gross and microscopic description. Lab Invest 1988;59:231–238.
6.
Kloth S, Gmeiner T, Aigner J, Jennings ML, Röckl W, Minuth WW: Transitional stages in the development of the rabbit renal collecting duct. Differentiation 1998;63:21–32.
7.
Tanner GA: Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 1998;9:1242–1248.
8.
Schafer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, Bachmann S: Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994;46:134–152.
9.
Takahashi H, Calvet JP, Dittemore-Hoover D, Yoshida K, Grantham JJ, Gattone VH II: A hereditary model of slowly progressive polycystic kidney disease in the mouse. J Am Soc Nephrol 1991;1:980–989.
10.
Alpern RJ, Preisig PA: Renal acid-base transport; in Schrier RW, Gottschalk CW (eds): Diseases of the Kidney, ed 6. New York, Little, Brown, 1997, pp 189–201.
11.
Rivas LJ, Hinchcliff KW, Kohn CW, Sams RA, Chew DJ: Effect of sodium bicarbonate administration of renal function of horses. Am J Vet Res 1997;58:664–667.
12.
Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 1997;30:703–709.
13.
Gattone VH II, Maser RL, Tian C, Branden MG: The urine concentrating defect and AVP-V2 receptor contribute to the progression of infantile-type murine polycystic kidney disease (PKD) (abstract). J Am Soc Nephrol 1997;8:372A.
14.
Gattone VH, Maser RL, Branden MG, Tiam C, Resenberg J: Collecting duct gene expression and effect of an AVP-V2 receptor antagonist on the progression of PKD in pcy mice (abstract). J Am Soc Nephrol 1998;9:19A.
15.
Torres VE: New insights into polycystic kidney disease and its treatment. Curr Opin Nephrol Hypertens 1998;7:159–169.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.